Navigation Links
Novel molecules developed at UB can boost vaccine potency

BUFFALO, N.Y. -- Two novel proteins studied by a University at Buffalo professor of microbiology and immunology appear to have the potential to enhance the production of antibodies against a multitude of infectious agents.

Terry D. Connell, Ph.D., professor of microbiology and immunology in the Witebsky Center for Microbial Pathogenesis in the UB School of Medicine and Biomedical Sciences, developed and patented the LT-IIa and LT-IIb entertoxins and their respective mutant proteins as new mucosal adjuvants, or boosters, that can enhance the potency of existing and future vaccines.

Connell and colleagues published five papers in 2007 describing their advances. They are the only research group in the scientific community investigating the immunology of these adjuvants.

The researchers currently are working to develop a safe and effective method to deliver the immune-enhancing molecules to the bodys mucous membranes -- the first line of defense against most pathogens -- to elicit protective immune responses on those membranes.

Almost every bacterium and virus that attacks us doesnt bore through the skin, said Connell. These infectious agents enter by colonizing the mucosal surfaces on the eye, sinuses, mouth, gut lining, lungs and genital tract.

To date Connell and colleagues have determined, using a mouse model, that the nasal passage is the best mucosal surface on which to apply LT-IIa and LT-IIb as mucosal adjuvants. Mixing a very small amount of LT-IIa or LT-IIb with an existing antigen and dripping the mixture into a mouses nose subsequently produces a strong antigen-specific immune response in the nasal passages, as well as in saliva, the urogenital tract and the bloodstream, their research showed.

In contrast, immunizing the mouse with only the antigen generates a much lower level antigen-specific immune response at those sites.

This method of application is particularly suitable for immunizing populations in underserved areas, said Connell.

If I want to immunize somebody in Uganda with a vaccine that must be injected, for instance, I have to bring needles, everything must be sterile and everything must be kept cold, which means we need refrigeration.

But if I can vaccinate through the nose, all I have to do is dry the antigen and my adjuvant. When I get to the middle of Uganda, I boil some water, pour in the antigen and adjuvant, stir it up, put it in an atomizer and sniff. The mixture doesnt even have to be sterile, because the nose isnt sterile.

Connell began studying the two adjuvants as a postdoctoral researcher at the Uniformed Services University of the Health Sciences (USUHS) in Washington, D.C., in 1989. The molecules had been isolated five years earlier by Randall Holmes, M.D., Ph.D., his post-doctoral advisor. Connell began his investigations into the activities of LT-IIa and LT-IIb at the USUHS by mapping the regions of the two enterotoxins that were important for receptor binding, toxicity and for assembly of the multisubunit proteins.

LT-IIa and LT -IIb are similar to cholera toxin in 3-dimentional structure and toxic activity. Yet, the amino-acid sequences of the binding subunits of LT-IIa and LT-IIb are significantly different from the amino-acid sequence of the binding subunit of cholera toxin. These amino acid differences underlie the specificity of LT-IIa and LT-IIb for ganglioside receptors, which are different from the ganglioside bound by cholera toxin. [A ganglioside is a complex molecule that contains both lipids and carbohydrates and is found in the outer membrane of many kinds of cells.]

Connell hypothesizes that it is these different ganglioside-binding activities that contribute to the unique immunological activities of LT-IIa and LT-IIb.

Basically, LT-IIa and LT-IIb are molecules you can add to any vaccine candidate to augment the immune response to that protein, whatever it may be, Connell stated.

The one problem researchers may encounter and on which they are working currently is to ensure that their vaccine booster doesnt travel to the brain via the olfactory nerve, or if the booster does traffic to the brain, that it doesnt have harmful properties. Connell said some of the mutant LT-IIa and LT-IIb adjuvants they have developed appear to exhibit no toxicity in cells, and thus have the potential to exert no harmful effects on neuronal cells. His molecules may be ready for human trials in a year, he said.


Contact: Lois Baker
716-645-5000 x1417
University at Buffalo

Related medicine news :

1. Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
2. Novel virus detection identifies new viruses in study of respiratory infections and asthma attacks
3. Researchers uncover novel mechanism that balances the sizes of functional areas in the brain
4. Novel Cooling Therapy May Have Aided Injured Football Player
5. ECLIPSE data on effects of Otsukas investigational novel treatment, Tolvaptan
6. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
7. GrantAdler Shipping Novel Implantable Vascular Access Port
8. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
9. Novel strategy under study for aggressive leukemia
10. ISTO Technologies Receives 510(k) Clearance for a Novel Bone Graft Substitute and Bone Graft Extender
11. 454 Sequencing(TM): Science Paper Describes a Novel, Highly Efficient Method of Sequencing Ancient DNA; Sequences the Mitochondria of 10 Individual Mammoths to Prove It
Post Your Comments:
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology: